Engineers Gate Manager’s Black Diamond Therapeutics BDTX Stock Holding History

Engineers Gate Manager’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-19,701	Closed	-$47.9K	–	2183
2025 Q4	$47.9K	Buy	19,701 +6,469	+49%	+$22.9K	﹤0.01%	1981
2025 Q3	$50.1K	Sell	13,232 -19,652	-60%	-$57.5K	﹤0.01%	2060
2025 Q2	$81.6K	Buy	+32,884	New	+$63.4K	﹤0.01%	2016
2025 Q1	–	Sell	-11,143	Closed	-$23.8K	–	2156
2024 Q4	$23.8K	Sell	11,143 -7,268	-39%	-$20.8K	﹤0.01%	2151
2024 Q3	$80.1K	Buy	18,411 +2,151	+13%	+$11.7K	﹤0.01%	1944
2024 Q2	$75.8K	Buy	+16,260	New	+$87.3K	﹤0.01%	1774

Other funds holding BDTX

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Engineers Gate Manager's BDTX Position: Q1 2026 in Review

Engineers Gate Manager sold out of Black Diamond Therapeutics (BDTX) in Q1 2026, closing a stake of 19,701 shares — an estimated $47.9K sold.

Engineers Gate Manager first reported a position in BDTX in Q2 2024 and held it in 6 quarters. The position peaked at $81.6K in Q2 2025. 104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.

Engineers Gate Manager reported no remaining Black Diamond Therapeutics position as of Q1 2026 after selling out during the quarter.
Engineers Gate Manager sold 19,701 Black Diamond Therapeutics shares in Q1 2026, an estimated $47.9K.
Engineers Gate Manager first reported a position in Black Diamond Therapeutics in Q2 2024 and held it in 6 quarters.
Engineers Gate Manager's Black Diamond Therapeutics position peaked at $81.6K in Q2 2025.
104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.

Based on Engineers Gate Manager's 13F filing for Q1 2026, filed 15 May 2026.